Investors

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

Financial Information

IMV Inc. is a clinical-stage immuno-oncology company dedicated to making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV's proprietary drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. Lead product candidate DPX-Survivac is currently being evaluated in several clinical trials in advanced ovarian cancer in combination with other innovative immunotherapy agents.

© 2018 IMV Inc. All rights reserved.

Clinical Trials
Ongoing Trials
●Expanded Access
●Investigator-initiated Trials
DPX-Survivac
 
Research & Development
Immuno-oncology
●Ovarian Cancer
 
Our Platform
Other Applications
●Infectious Diseases
Intellectual Property
Publications
About Us
Leadership
Board of Directors
Company History
Business Development
Partnerships
SCAC
 
Investors
Investment Highlights
Stock Information
Press Releases
Analyst Coverage
Events, Webcasts and Presentations
Financial Information
Tax Information
Proxy Information
SEC Filings
SEDAR Filings
Corporate Governance
Investors FAQs
Contact Us
Newsroom
Archives
Media Contact
 
Contact Us
 
Careers
Openings
Life at IMV
Life in Halifax
IMV Inc.

130 Eileen Stubbs Avenue,
Suite 19
Dartmouth, Nova Scotia B3B 2C4

Tel: +1 902.492.1819
Fax: +1 902.492.0888

 

Québec Office 
2875 Boulevard Laurier 
Delta 1, Suite 220 
Québec, Québec, Canada 
G1V 2M2 
Tel: +1 581.741.0519

 

Legal
Privacy
Cookies
Social Media

 

© 2018 IMV Inc. All rights reserved.